These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 23170907)

  • 1. Removal of TSE agent from plasma products manufactured in the United Kingdom.
    Roberts PL; Dalton J; Evans D; Harrison P; Li Z; Ternouth K; Thirunavukkarasu V; Bulmer M; Fernando S; McLeod N
    Vox Sang; 2013 May; 104(4):299-308. PubMed ID: 23170907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prion-removal capacity of chromatographic and ethanol precipitation steps used in the production of albumin and immunoglobulins.
    Thyer J; Unal A; Thomas P; Eaton B; Bhashyam R; Ortenburg J; Uren E; Middleton D; Selleck P; Maher D
    Vox Sang; 2006 Nov; 91(4):292-300. PubMed ID: 17105604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elimination capacity of a TSE-model agent in the manufacturing process of Alphanate/Fanhdi, a human factor VIII/VWF complex concentrate.
    Diez JM; Caballero S; Belda FJ; Otegui M; Gajardo R; Jorquera JI
    Haemophilia; 2009 Nov; 15(6):1249-57. PubMed ID: 19563480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prion removal effect of a specific affinity ligand introduced into the manufacturing process of the pharmaceutical quality solvent/detergent (S/D)-treated plasma OctaplasLG.
    Neisser-Svae A; Bailey A; Gregori L; Heger A; Jordan S; Behizad M; Reichl H; Römisch J; Svae TE
    Vox Sang; 2009 Oct; 97(3):226-33. PubMed ID: 19548963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Partitioning of human and sheep forms of the pathogenic prion protein during the purification of therapeutic proteins from human plasma.
    Stenland CJ; Lee DC; Brown P; Petteway SR; Rubenstein R
    Transfusion; 2002 Nov; 42(11):1497-500. PubMed ID: 12421224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current strategies to prevent transmission of prions by human plasma derivatives.
    Burnouf T; Padilla A
    Transfus Clin Biol; 2006 Nov; 13(5):320-8. PubMed ID: 17254822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Capacity of the manufacturing process of Flebogamma(®) DIF, a new human high purity intravenous immunoglobulin, to remove a TSE model-agent.
    Diez JM; Caballero S; Belda F; Otegui M; Gajardo R; Jorquera JI
    Biologicals; 2010 Nov; 38(6):670-4. PubMed ID: 20863716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TSE clearance during plasma products separation process by Gradiflow(TM).
    Wang K; Johnson A; Obradovic M; Anderson G; Maclean C; Nair H
    Biologicals; 2005 Jun; 33(2):87-94. PubMed ID: 15939286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prion removal capacity of plasma protein manufacturing processes: a data collection from PPTA member companies.
    Cai K; Gröner A; Dichtelmüller HO; Fabbrizzi F; Flechsig E; Gajardo R; von Hoegen I; Jorquera JI; Kempf C; Kreil TR; Lee DC; Moscardini M; Pölsler G; Roth NJ
    Transfusion; 2013 Sep; 53(9):1894-905. PubMed ID: 23252676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Studies on the removal of abnormal prion protein by processes used in the manufacture of human plasma products.
    Foster PR; Welch AG; McLean C; Griffin BD; Hardy JC; Bartley A; MacDonald S; Bailey AC
    Vox Sang; 2000; 78(2):86-95. PubMed ID: 10765143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the protection of primates transfused with variant Creutzfeldt-Jakob disease-infected blood products filtered with prion removal devices: a 5-year update.
    Lescoutra-Etchegaray N; Jaffré N; Sumian C; Durand V; Correia E; Mikol J; Luccantoni-Freire S; Culeux A; Deslys JP; Comoy EE
    Transfusion; 2015 Jun; 55(6):1231-41. PubMed ID: 25647476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pall leukotrap affinity prion-reduction filter removes exogenous infectious prions and endogenous infectivity from red cell concentrates.
    Sowemimo-Coker SO; Pesci S; Andrade F; Kim A; Kascsak RB; Kascsak RJ; Meeker C; Carp R
    Vox Sang; 2006 May; 90(4):265-75. PubMed ID: 16635068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Removal of TSE agents by depth or membrane filtration from plasma products.
    Roberts PL; Evans D; Harris L
    Biologicals; 2010 Jan; 38(1):158-61. PubMed ID: 19854662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CJD PrPsc removal by nanofiltration process: application to a therapeutic immunoglobulin solution (Lymphoglobuline).
    Truchot L; Arnaud T; Bloy C; Perret-Liaudet A
    Biologicals; 2006 Sep; 34(3):227-31. PubMed ID: 16490361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Partitioning of TSE infectivity during ethanol fractionation of human plasma.
    Gregori L; Maring JA; MacAuley C; Dunston B; Rentsch M; Kempf C; Rohwer RG
    Biologicals; 2004 Mar; 32(1):1-10. PubMed ID: 15026020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. UK approach to assessing assays and filters designed to reduce the risk of transfusion-transmitted vCJD.
    Thomas S; Turner ML; Williamson LM
    Transfus Clin Biol; 2013 Sep; 20(4):405-11. PubMed ID: 23928183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preparation of soluble infectious samples from scrapie-infected brain: a new tool to study the clearance of transmissible spongiform encephalopathy agents during plasma fractionation.
    Berardi VA; Cardone F; Valanzano A; Lu M; Pocchiari M
    Transfusion; 2006 Apr; 46(4):652-8. PubMed ID: 16584444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasminogen-based capture combined with amplification technology for the detection of PrP(TSE) in the pre-clinical phase of infection.
    Segarra C; Bougard D; Moudjou M; Laude H; Béringue V; Coste J
    PLoS One; 2013; 8(7):e69632. PubMed ID: 23894513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Removal of TSE agents from blood products.
    Foster PR
    Vox Sang; 2004 Jul; 87 Suppl 2():7-10. PubMed ID: 15209867
    [No Abstract]   [Full Text] [Related]  

  • 20. Distribution of a bovine spongiform encephalopathy-derived agent over ion-exchange chromatography used in the preparation of concentrates of fibrinogen and factor VIII.
    Foster PR; Griffin BD; Bienek C; McIntosh RV; MacGregor IR; Somerville RA; Steele PJ; Reichl HE
    Vox Sang; 2004 Feb; 86(2):92-9. PubMed ID: 15023177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.